AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02086149 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic Exercise
Description: 12-week moderate-intensity behavioral exercise intervention. Weekly sessions with an exercise physiologist who will also assign weekly exercise goals. Two month course of the nicotine patch initiated during week 5.
Study NCT02086149 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Health Education
Description: 12-week health education control. Weekly sessions about 12 different topics related to the health effects of smoking, led by an expert in smoking cessation.
Study NCT03887026 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Norketotifen
Description: Norketotifen oral capsule
Study NCT04128644 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Thoughts & health
Description: 12 sessions of Thoughts \& Health. Baseline questionaires and follow up assessments
Study NCT03887026 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo oral capsule
Study NCT01727479 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ribose
Description: After each of the 3km time trial (3 in total), participants will be asked to drink the experimental product (or placebo) incorporated in a sports drink.
Study NCT01727479 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02551471 — intervention group
Intervention type: OTHER
Intervention: MDT (Multidisciplinary team) meeting observation
Description: 3 per centre with real patient cases and theoretical patient cases (blinded pelvic MRI re-reading).
Study NCT02084732 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib
Description: drug
Study NCT02598661 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imetelstat
Description: Intravenous injection.
Study NCT04128644 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Treatment as Usual
Description: Baseline questionnaires and follow up assessments, intervention as usual, Student Health
Study NCT02837978 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tacrolimus
Description: Tacrolimus capsule: 0.5mg to 1mg, po, twice per day (Bid)，adjusted by its concentration in blood or due to patient response. Then may titer down until the endpoint.
Study NCT02837978 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Tacrolimus capsule: 0.5mg to 1mg, po, twice per day (Bid)，adjusted by its concentration in blood or due to patient response. Then may titer down until the endpoint.
Study NCT02598661 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching Placebo to Imetelstat will be administered.
Study NCT04801680 — intervention group
Intervention type: DEVICE
Intervention: Mpact 3D metal cup
Description: Subjects, among those whose clinical condition makes them eligible for a primary total hip arthroplasty, will be invited to participate to the study during preoperative visit. They'll receive the Mpact 3D metal cup device
Study NCT02837978 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MTX
Description: MTX：5mg to 15mg, po, once per week (Qw) until the endpoint or adjusted due to unacceptable toxicity develops.
Study NCT05029323 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Fast HUTT
Description: Fast HUTT protocol stabilization phase of 5 min in the supine position; passive phase of 10 min at a tilt angle of 60 degrees; provocation phase of further 10 min after 300 micrograms NTG sublingual spray.
Study NCT05029323 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Conventional HUTT
Description: Conventional HUTT protocol stabilization phase of 5 min in the supine position; passive phase of 20 min at a tilt angle of 60 degrees; provocation phase of further 15 min after 300 micrograms NTG sublingual spray.
Study NCT01371578 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GS-5885 tablet
Description: 30 mg active tablet
Study NCT04432701 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: proactive extubation
Description: when children is breathing spontaneously and adequately in PACU,endotracheal tube was removed directly
Study NCT03748290 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregabalin
Description: Pregabalin 75 mg for 12 weeks
Study NCT03748290 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: Placebo Oral Tablet
Study NCT01371578 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GS-9451 tablet
Description: two active 100 mg tablets
Study NCT01371578 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: peginterferon alfa-2a
Description: peginterferon alfa-2a (solution for injection) 180 µg/week
Study NCT01371578 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ribavirin tablet
Description: ribavirin tablet (weight based: 1000 mg/day \<75 kg; 1200 mg/day ≥ 75 kg) divided twice daily (BID); tablet
Study NCT03644095 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mucinex® SE
Description: Single dose of Mucinex® SE extended-release 600 mg bi-layer tablet
Study NCT03644095 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vicks Cough Syrup for Chesty Coughs
Description: Vicks Cough Syrup for Chesty Coughs 15 mL (200 mg guaifenesin q4h) immediate release (IR) syrup
Study NCT03080181 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pasireotide 0.6 MG/ML
Description: The aim of the study was to evaluate the effect of pasireotide on β -cell and adipose function in patients with Cushing's disease (CD).
Study NCT00788528 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-2367 (velneperit)
Description: Tablet, 4 x 400 mg, taken once daily with morning meal, 54-weeks
Study NCT04182750 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacist consultation
Description: The intervention is a patient-centered consultation that will last about 15 minutes. The intervention is defined as A planned, individualized, and structured conversation with the purpose to relieve pregnant women for any concern and answer questions she may have regarding self-care ailments and medication use in pregnancy. Specifically, the consultation will:~* Answer any questions the participants may have within pharmaceutical care.~* Improve pregnant women's understanding of common pregnancy-related ailments and hence contribute to better management of the ailments.~* Raise awareness, provide confidence, and give information about safe medications options in pregnancy~* Focus on preventative measures for NVP.~* Contribute to better adherence for needed/chronic medication throughout the pregnancy.~The pharmacists will beforehand have access to the women´s answers from the baseline questionnaire Q1, including information about her medical conditions and medication use.
Study NCT03198702 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A injection
Description: A total of 8UI/kg will be injected in the internal shoulder rotator muscles: 2UI/kg in the sub scapular muscle, 3UI/kg in the pectoralis major muscle and 3UI/kg in the teres major/latissimus dorsi muscle.
Study NCT03198702 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham
Description: The injection is mimed, the procedure is the same as the botulinum toxin injection.
Study NCT00130520 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: 10mg/kg every two weeks IV-bevacizumab
Study NCT00130520 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erlotinib
Description: 150mg daily by mouth-erlotinib
Study NCT03918863 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neuromuscular electrical stimulation
Description: Exercise protocol associated with neuromuscular electrical stimulation on vastus medialis and gluteus medius. Parameters: rectangular pulse shape, biphasic, symmetrical, pulse duration of 200μs, interbust interval of 10ms and frequency of 2.500Hz modulated in 50 bursts.
Study NCT03918863 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: Same protocol of exercises of the other group, without association of electrical stimulation.
Study NCT03788681 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Estradiol Valerate
Description: oral estradiol  estradiol valerate  (Cyclo-Progynova)
Study NCT03788681 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: placebo
Study NCT02257359 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epelsiban
Description: Epelsiban will be supplied as a 25 mg white to off-white round direct compression oral tablet.
Study NCT00621179 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leuprolide acetate in depot suspension
Description: Leuprolide acetate in depot suspension 3.75 mg intramuscularly every 28 days x 3
Study NCT00621179 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No intervention
Study NCT04087668 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Monitored Anesthesia Care
Description: MAC was induced and maintained via the continuous infusion of propofol AND remifentanil using a target-controlled infusion (TCI) pump. The appropriate level of sedation was 65 to 80 points on BIS. The adjunctive sedatives (eg, fentanyl, midazolam) was at the discretion of the anesthesia team.
Study NCT04087668 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: General Anesthesia
Description: Induction was done with propofol (2 mg/kg) , cis-atracurium (0.15 mg/kg) , and fentanyl (5μg/kg). After orotracheal intubation, general anesthesia was maintained with sevoflurane (1-1.3MAC) , propofol (3mg/kg/h), remifentanil (0.05-0.2 ug/kg/min) and repetitive doses of 0.1mg atracurium per kilogram were administered. After the procedure was completed, neostigmine mixed with atropine was used as a reversal agent for the neuromuscular blockade, and the patient was extubated when the recovery from anesthesia was confirmed.The BIS was 45 to 60 points .
Study NCT04087668 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Induction Without Neuromuscular Blockade
Description: Anaesthesia was induced with propofol (2 mg/kg), remifentanil(3 ug/kg) and 2% lidocaine (1 mg/kg). Nasotracheal intubation was performed 60 s after the administration. After intubation, general anesthesia was sevoflurane (1-1.3MAC) , propofol (3mg/kg/h), remifentanil (0.05-0.2 ug/kg/min). After the procedure was completed, the patient was extubated when the recovery from anesthesia was confirmed.The BIS was 45 to 60 points .
Study NCT00593879 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Mecamylamine
Description: 2.5mg mecamylamine Hcl, tablet form taken twice a day (total of 5.0mg). For 7.5 mg dose group, 2 tablets taken morning, one tablet evening. At 10.0mg, 2 tablets taken twice daily.
Study NCT01914835 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Chess
Description: The Motivational Chess (MC) combines Motivational Interviewing with chess game. Volunteers are submitted to 10 sessions of 90 minutes, over three weeks (total 15 hours: 10 hours of chess practice and 5 hours of motivational interviewing).~The Active Control (AC) group consists of ten structured activities using cardboard, paper, crayons, among others. Volunteers are submitted to 10 sessions of 90 minutes, over three weeks (total 15 hours: 10 hours of recreational activities and 5 hours of information about basic cognitive functions).
Study NCT02579876 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Viaskin Milk 500 mcg
Description: Biological: Viaskin Milk 500 mcg Subjects epicutaneously administered daily (up to 24 hours application per day) with a patch containing 500 mcg cow's milk proteins.
Study NCT00593879 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mecamylamine
Description: 2.5mg mecamylamine Hcl, tablet form taken twice a day (total of 5.0mg). For 7.5 mg dose group, 2 tablets taken morning, one tablet evening. At 10.0mg, 2 tablets taken twice daily.
Study NCT04738279 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Non-Invasive Continuous Remote Patient Monitoring
Description: Continuous remote patient monitoring will consist of continuous collection of physiological data and patient status through a non-invasive wearable solution, connected to a structured cascading escalation management pathway
Study NCT04738279 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Affective Analysis of Participant Response to Continuous Remote Patient Monitoring
Description: Survey and qualitative interviewing of participants
Study NCT02243020 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Vagus Nerve Stimulation (VNS)
Study NCT02243020 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vagus Nerve Stimulation (VNS)
Study NCT01593527 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACZ885
Description: Canakinumab 150 mg s.c.
Study NCT01593527 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triamcinelone acetonide
Description: Triamcinelone acetonide 40 mg i.m.
Study NCT01201746 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Delayed treatment
Description: Scaling, Root Planing and oral hygiene instruction
Study NCT01201746 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Periodontal therapy
Description: Scaling, root planning and oral hygiene instructions
Study NCT03972982 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simplified intensive insulin therapy regimen
Description: Short-term continuous subcutaneous insulin infusion to maitain near normoglycemica for 1 week, thereafter basal insulin and metformin were subsequently used. Wearable devices and smart apps will be used for lifestyle modification.
Study NCT03728348 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: mt-sDNA screening test
Description: Stool samples will be collected by the subject for the mt-sDNA screening test.
Study NCT03728348 — intervention group
Intervention type: PROCEDURE
Intervention: Colonoscopy
Description: Subjects will undergo a screening colonoscopy.
Study NCT02587390 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcabene 900 mg
Description: 3x300 mg Gemcabene tablets orally once daily (QD) for 15 days
Study NCT03972982 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Traditional Short-term Intensive insulin therapy
Description: Short-term continuous subcutaneous insulin infusion will be initiate to maitain near normoglycemica for 2 weeks, then patients will be ordinarily follow-up
Study NCT03410381 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Application EMMA
Description: Emma proposes four types of assessments during 6 months:1) 5 times a day during 3 days, every month (5 minutes): patients can assess their emotions, their thoughts, their behavior and their occurrence context. 2) Weekly (7 minutes): consists of a summary of the week, about their emotions, thoughts, behavior, their relationships (family, work, friends, and their quality of life.3) Monthly (5 minutes): assessment of the usefulness and satisfaction about the application.4) Assessment available at any time An action plan is designed to support the participants, to help them facing difficult emotions and feelings, and to encourage them to ask for help. They can contact a relative or call the psychiatric emergency service directly by clicking on a button.
Study NCT01170364 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sibutramine
Description: 1 week of active sibutramine (15mg)
Study NCT02579876 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Viaskin Placebo
Description: Biological: Viaskin Placebo Subjects epicutaneously administered daily (up to 24 hours application per day) with a patch containing a matching placebo formulation.
Study NCT03369275 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Allogeneic Bone Marrow-Derived Human Mesenchymal Stem Cells
Description: Cryopreserved Allogeneic Bone Marrow-Derived Human Mesenchymal Stem Cells will be administered intravenously.
Study NCT02587390 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simvastatin 80 mg
Description: 2x40 mg Simvastatin tablets orally once daily (QD) for 15 days
Study NCT03369275 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, with excipients, will be administered intravenously.
Study NCT01501708 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Caspofugin based combination therapy
Description: Caspofungin: 70 mg on the ﬁrst day of therapy, followed by 50 mg q.d.~* All patients received azoles as prophylaxis (fluconazole as prophylaxis and itraconazole or voriconazole as secondary prophylaxis), combination with liposomal amphotericin B at a dosage 3mg/kg q.d will be given.~* In case of renal function damage, combination with voriconazole 6mg/kg followed by 4 mg/kg b.i.d. will be given.
Study NCT01821742 — intervention group
Intervention type: OTHER
Intervention: Ultrasound cardiac output measurement
Study NCT02884297 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Contrast agent: SonoVue®.
Description: SonoVue® Injection: will be done through the peripheral venous way already set up by the anesthetist for its injection. None venous dedicated way will be established. The injection will take place when the woman will be under general anesthesia, ventilated and under constant cardio-respiratory monitoring.
Study NCT04402866 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TD-0903
Description: Study Drug to be administered by inhalation
Study NCT04402866 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo to be administered by inhalation
Study NCT01170364 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 2 weeks of placebo
Study NCT02587390 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Simvastatin 80 mg
Description: 2x40 mg Simvastatin tablets orally once daily (QD) for 15 days
Study NCT02896062 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: sleep-coaching
Description: Sleep-coaching with elements of cognitive behavioral therapy for insomnia and general information about sleep
Study NCT02896062 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: sleep-coaching
Description: Sleep-coaching with elements of cognitive behavioral therapy for insomnia and general information about sleep
Study NCT02166424 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Omega-3 polyunsaturated fatty acids
Study NCT02166424 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Olive oil
Study NCT01102244 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tobradex ST
Description: tobramycin / dexamethasone ophthalmic suspension 0.3%/0.05% 1 drop 4 times daily for 14 days
Study NCT01102244 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azasite
Description: azithromycin 1% 1 drop twice daily for 2 days, then once daily for 12 days
Study NCT01107860 — intervention group
Intervention type: DEVICE
Intervention: Computed Tomography
Description: In Group I, fifty CBCT studies will be performed. The objectives will be to illustrate the capacity of CBCT to image the breast in its entirety as compared with the gold standard mammographic exam.
Study NCT01107860 — intervention group
Intervention type: DEVICE
Intervention: Computed Tomography
Description: In Group II , at least three hundred and fifty (350) study participants, who require diagnostic evaluation of the breast will undergo a breast CBCT . These subjects may be referred for biopsy as a result of a finding from a mammogram, ultrasound, MRI, or clinical exam.
Study NCT00815295 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib
Description: Phase 1 - Dose level 1 : Sorafenib will be given 200 mg twice daily oral, Phase 1 - Dose level 2 : Sorafenib will be given 400 mg twice daily oral, Phase 2 : Sorafenib will be given at the maximum tolerated dose from Phase 1
Study NCT03366480 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABTL0812 in combination with paclitaxel and carboplatin
Description: ABTL0812 in combination with paclitaxel and carboplatin.
Study NCT04638764 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Aerobic interval training combined with high intensity resistance training
Description: Patients enrolled in arm of the study will perform 12 weeks of combined aerobic interval training (5 intervals of cycling at the intensity of 50 %-80% of peak power obtained at baseline cardiopulmonary testing) combined with high intensity resistance training (3 sets of leg press at the intensity of 70 %- 80 % of one repetition maximum (1-RM)).
Study NCT04638764 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Aerobic interval training combined with low intensity resistance training
Description: Patients enrolled in arm of the study will perform 12 weeks of combined aerobic interval training (5 intervals of cycling at the intensity of 50 %-80% of peak power obtained at baseline cardiopulmonary testing) combined with high intensity resistance training (3 sets of leg press at the intensity of 30 %- 40 % 1-RM).
Study NCT04638764 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Aerobic interval training
Description: Patients enrolled in arm of the study will perform 12 weeks of aerobic interval training (5 intervals of cycling at the intensity of 50 %-80% of peak power obtained at baseline cardiopulmonary testing).
Study NCT00256269 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: 40 mg/m2 IV over 60 minutes Every 21 days
Study NCT00256269 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: 60 mg/m2 IV over 60 minutes, immediately following oxaliplatin Every 21 days